FluMist is a nasal spray manufactured by AstraZeneca that has been used to protect against influenza in the United States ...
In a first, the US Food and Drug Administration on Friday approved a nasal spray flu vaccine for self-administration ...
The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the first “self-administered” influenza vaccine — though a delay in the change ...
Recent health developments include the EU backing Novo Nordisk's Wegovy for obesity-related heart conditions, FDA approvals ...
A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.
AstraZeneca's FluMist influenza vaccine, which can be self-administered. Experts hope an option for at-home flu vaccination ...
On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...
The FDA Friday approved the flu vaccine that can be done at home and does not need to be administered by a health care provider.
The FDA is clearing the way for an at-home flu vaccines. A self-administered version of pharmaceutical giant AstraZeneca’s ...
The Food and Drug Administration on Friday approved the first at-home flu vaccine, a nasal spray that consumers with a ...
The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...
The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007, was first approved by the FDA in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback